RXRX vs DNLI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

RXRX

38.9
AI Score
VS
DNLI Wins

DNLI

72.2
AI Score

Investment Advisor Scores

RXRX

39score
Recommendation
SELL

DNLI

72score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RXRX DNLI Winner
Revenue 14.14M 3.60M RXRX
Net Income -248.51M -256.00M RXRX
Net Margin -1757.1% -7103.2% RXRX
Operating Income -263.47M -267.90M RXRX
ROE -27.2% -30.7% RXRX
ROA -20.5% -22.1% RXRX
Total Assets 1.21B 1.16B RXRX
Cash 545.68M 201.53M RXRX
Current Ratio 5.03 8.37 DNLI
Free Cash Flow -187.35M -231.48M RXRX

Relative Price Performance (Last 90 Days)

RXRX 1M: +19.1% · 3M: +1.6% DNLI 1M: -12.4% · 3M: -22.2%

Current Technical Phase

RXRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 60

RSI (14): 59.6 · Price: $4.03

DNLI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 36

RSI (14): 36.3 · Price: $20.02

Fundamentals Snapshot

Metric RXRX DNLI
Market Cap — —
Forward P/E -4.5 -8.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.6% -1.0%
Gross Margin -7.2% -110.2%
Operating Margin -17.6% -36.0%
EPS -1.02 -2.84
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNLI is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.